U.S. President Donald Trump has signed an executive order directing federal agencies to loosen regulations on marijuana, a move that could mark one of the most significant changes in U.S. cannabis policy in decades. The order instructs the attorney general to move quickly toward reclassifying marijuana under the Controlled Substances Act, potentially shifting it from Schedule I to Schedule III.
If reclassified, marijuana would be grouped with drugs such as certain painkillers, ketamine, and testosterone, which are considered to have accepted medical uses and lower abuse potential. While marijuana would remain illegal at the federal level, the change could dramatically reshape the cannabis industry by expanding medical research opportunities, improving access to funding, and easing barriers for banks and institutional investors.
Trump defended the decision by emphasizing patient needs, saying many Americans suffering from chronic pain have pushed for greater access to marijuana-based treatments. Although he reiterated that he does not personally use the drug and remains cautious about controlled substances, he acknowledged its growing demand and medical relevance.
The move drew mixed reactions in Washington. Senate Democratic Leader Chuck Schumer welcomed the order, calling it a step toward long-overdue reform. In contrast, dozens of Republican lawmakers urged Trump not to proceed, arguing that reclassification could send the wrong message to children, empower drug cartels, and increase safety risks on U.S. roads.
Industry experts noted that congressional action would still be required to establish stable nationwide cannabis regulations. The Drug Enforcement Administration must now review the recommendation, a process that has historically been slowed by bureaucracy. Even with reclassification, marijuana would still face federal restrictions and criminal penalties.
Cannabis stocks initially rose on the news but later fell as investors realized the order did not include provisions for cannabis banking reform. Limited access to traditional financing remains a major challenge for marijuana companies, contributing to high operating costs and the persistence of black-market activity.
Public opinion continues to favor legalization, with most Americans supporting broader reform. Combined with previous efforts, including reviews initiated under former President Joe Biden, Trump’s order signals a continued shift toward easing long-standing federal marijuana policies while leaving the final outcome uncertain.


Trump Administration Proposes Sweeping Limits on Gender-Affirming Care for Children
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
U.S. Homeland Security Ends TSA Union Contract, Prompting Legal Challenge
Canada Signals Delay in US Tariff Deal as Talks Shift to USMCA Review
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development
U.S. State Department Reverts to Times New Roman in Push for “Professionalism”
NSW to Recall Parliament for Urgent Gun and Protest Law Reforms After Bondi Beach Shooting
Kennedy Center Reportedly Renamed Trump-Kennedy Center After Board Vote
Dan Bongino to Step Down as FBI Deputy Director After Brief, Controversial Tenure
Trump Expands U.S. Travel Ban to Antigua and Barbuda, Dominica, Sparking Economic Fears in the Caribbean
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs
California, 18 States Sue to Block Trump’s $100,000 H-1B Visa Fee
UN Warns Gaza Humanitarian Aid at Risk as Israel Registration Rules Threaten NGO Operations
Trump Administration Unveils High-Priced “Trump Gold Card” Visa Program
U.S. House Advances GOP Healthcare Bill as ACA Subsidies Near Expiration 



